1985-2000
|
2000-2004
|
2005-2008
|
Current
|
|
Research to market
|
Dual business model
|
Dual business model under pressure
|
Acquisition
|
|
1985/86 - Start-up in Gent and Antwerp
|
Increased focus on Therapeutics |
2005 - Roche PCR
license |
2008 - Solvay Pharmaceuticals NV acquired Innogenetics NV |
|
1994 - Sales in infectious diseases
|
2001 - Spin-off XCELLentis NV
(wound healing) |
2006 - Favourable ruling on Abbott Laboratories litigation |
|
|
Pioneering in the area of multiparameter testing - INNO-LIA™ and INNO-LiPA strips
|
2001/05 - R&D cooperation with Roche Diagnostics GmbH(SeptiFast®) and Siemens Healthcare Diagnostics (HCV genotyping) |
2006 - CellTran Ltd. acquired assets of XCELLentis NV |
|
|
1996 - IPO with €10m in sales
|
2004 - €45m Diagnostics trade sales
|
2007 - Results and discontinuation phase IIb trial in HCV
|
|
2000 - Approximately €30m
sales |
2004 - Agreement with PamGene International BV |
2008 - Termination Therapeutics activities |
|